Pep-Compass

Updated October 2026 | Pep Compass

Weight-loss peptides have become one of the most discussed areas of metabolic research, and for good reason. Clinical trials are reporting levels of weight reduction that would have been difficult to imagine with medication just a decade ago.

But not all peptides work the same way, and not all of them have the same level of research behind them.

Semaglutide and tirzepatide are already established prescription treatments for obesity. Retatrutide is producing some of the most impressive results seen in clinical trials so far. Cagrilintide is also attracting attention, particularly when studied alongside semaglutide.

So which compounds are showing the strongest results?

Let’s compare the published findings, what makes each peptide different, and where the research stands in 2026.

Comparing Weight-Loss Peptides: What Do the Studies Show?

The following results come from clinical trials involving adults with obesity or overweight who met specific enrollment criteria.

These numbers are not a head-to-head comparison. They come from different studies, with different participants, treatment approaches, and methods of measuring outcomes. The retatrutide and tirzepatide figures also represent results at the higher studied doses.

Still, the findings give us a useful picture of how these compounds compare and why certain peptides are generating so much research interest.

1. Retatrutide: One of the Most Promising Peptides in Weight-Loss Research

Retatrutide has become a major focus of obesity research because of its unusually strong clinical trial results.

Unlike medications that target one or two hormone pathways, retatrutide targets three:

• GLP-1, which influences appetite and feelings of fullness
• GIP, which contributes to metabolic and insulin regulation
• Glucagon, which plays a role in energy metabolism

This combination has earned retatrutide the description triple agonist.

What does the research show?

An earlier Phase 2 clinical trial reported an average weight reduction of 24.2% after 48 weeks at the highest studied dose.

More recently, the Phase 3 TRIUMPH-1 trial reported average weight loss of 28.3% over 80 weeks in its highest-dose group. Those results were published in September 2026.

For perspective, 28.3% of an initial body weight of 250 pounds would equal approximately 71 pounds. This is only an illustration of the percentage, not an individual weight-loss prediction.

These findings are particularly interesting because they suggest that targeting three hormone pathways could produce greater weight reduction than targeting GLP-1 alone.

Why researchers are watching retatrutide

Retatrutide is helping researchers investigate whether combining appetite regulation with additional metabolic pathways can produce more substantial weight loss.

However, retatrutide remains investigational and is not FDA-approved. Its long-term safety, appropriate clinical use, and benefit-risk profile require continued evaluation.

Research: Retatrutide Phase 3 TRIUMPH-1, New England Journal of Medicine (2026)

2. Tirzepatide: Strong Results With an Established Clinical Track Record

Tirzepatide is one of the most extensively studied and effective currently approved peptide-based medications for weight management.

It targets two hormone pathways:

• GLP-1
• GIP

These pathways influence appetite, fullness, blood sugar regulation, and food intake.

What does the research show?

In the SURMOUNT-1 trial, participants receiving the highest studied dose of tirzepatide experienced an average weight reduction of 20.9% after 72 weeks.

The study involved more than 2,500 adults with obesity or overweight and a weight-related complication, without diabetes.

A weight reduction of this magnitude is significant, especially considering the lower average results historically associated with many earlier weight-loss medications.

Why tirzepatide stands out

Tirzepatide has an advantage that newer investigational compounds do not yet have: extensive clinical research and an established FDA-approved obesity treatment.

Its effectiveness has also made the relationship between GLP-1 and GIP pathways an important area of continued research.

Research: SURMOUNT-1 Trial, New England Journal of Medicine (2022)

3. Semaglutide: The Peptide That Helped Change Obesity Treatment

Semaglutide was one of the major breakthroughs that brought GLP-1 research into the mainstream.

Unlike tirzepatide and retatrutide, semaglutide targets a single primary hormone pathway, GLP-1.

Its effects include reducing appetite, increasing feelings of fullness, and helping regulate blood glucose.

What does the research show?

The STEP 1 clinical trial found that participants receiving semaglutide experienced an average weight reduction of 14.9% over 68 weeks.

By comparison, participants receiving placebo lost an average of 2.4%.

Semaglutide helped establish that medications targeting appetite-regulating hormones could produce meaningful and sustained weight loss.

Why semaglutide remains important

Although newer compounds have reported higher average weight-loss percentages, semaglutide remains an important part of obesity research.

Its established clinical evidence, approved medical applications, and continued investigation in combination therapies make it one of the foundational compounds in this field.

Research: STEP 1 Trial, New England Journal of Medicine (2021)

4. Cagrilintide: A Different Approach to Appetite Regulation

Cagrilintide is particularly interesting because it works differently from the GLP-1 medications discussed above.

It is a long-acting amylin analog.

Amylin is a hormone involved in appetite regulation, feelings of fullness, and how quickly food leaves the stomach.

Rather than targeting the same pathways as semaglutide or tirzepatide, cagrilintide offers researchers another approach to regulating food intake.

What does the research show?

In the REDEFINE 1 trial, cagrilintide alone produced an average weight reduction of 11.5% over 68 weeks.

That result was lower than the figures reported for several GLP-1-based treatments, but the study also examined what happens when cagrilintide is combined with semaglutide.

And that is where things get interesting.

5. Cagrilintide + Semaglutide: Why Combination Research Matters

The combination of cagrilintide and semaglutide, known as CagriSema, is one of the more promising areas of ongoing obesity research.

The idea is relatively straightforward.

Semaglutide targets GLP-1 pathways, while cagrilintide works through amylin pathways. Combining these approaches may produce greater appetite regulation and weight reduction than either compound alone.

What does the research show?

In the REDEFINE 1 trial, average weight reduction after 68 weeks was:

• 20.4% with CagriSema
• 14.9% with semaglutide alone
• 11.5% with cagrilintide alone
• 3.0% with placebo

This is particularly useful research because all four treatment groups were evaluated within the same trial.

The combination demonstrated significantly greater weight loss than placebo, supporting continued investigation of treatments that target multiple appetite-regulating pathways.

Cagrilintide and CagriSema remain investigational rather than FDA-approved weight-loss treatments.

Research: REDEFINE 1 Trial, New England Journal of Medicine (2025)

Does More Weight Loss Automatically Mean a Better Peptide?

Not necessarily.

The highest reported weight-loss percentage is only one part of evaluating a compound.

Researchers also consider:

• Safety: What side effects occur, and how frequently?
• Tolerability: How many participants can continue treatment?
• Sustainability: What happens to weight after treatment ends?
• Study quality: How large and well-controlled was the trial?
• Long-term outcomes: Do improvements extend beyond the number on the scale?

Gastrointestinal side effects such as nausea, vomiting, diarrhea, and constipation have been commonly reported in studies of these treatments. More serious complications and individual medical risks also need to be considered.

Another important distinction is that results from regulated clinical trials cannot automatically be applied to products sold through research peptide suppliers. Identity, purity, manufacturing quality, and appropriate testing all matter.

A compound showing impressive results in a clinical trial does not establish the safety or effectiveness of every product marketed under the same chemical name.

So Which Weight-Loss Peptide Has the Strongest Research?

Based on the clinical evidence available in October 2026, several conclusions stand out.

Retatrutide has produced the largest average weight-loss percentage among the treatments reviewed here. Its Phase 3 results make it one of the most closely watched investigational obesity treatments.

Tirzepatide has some of the strongest evidence among established, FDA-approved weight-loss treatments. Its effectiveness and broader clinical track record make it an important benchmark for newer compounds.

Semaglutide remains foundational to modern obesity research. Its clinical success helped establish the potential of GLP-1-based weight management.

Cagrilintide is particularly interesting in combination research. Results from REDEFINE 1 demonstrate why researchers continue investigating therapies that work through different hormone pathways.

There is no single compound that can be declared the best option for every individual. The research is evolving, and effectiveness needs to be considered alongside safety, study limitations, and regulatory status.

Final Thoughts

One of the biggest developments in weight-loss peptide research is the movement from single-pathway treatments toward compounds that influence multiple hormone systems.

Semaglutide demonstrated what targeting GLP-1 could accomplish. Tirzepatide expanded that approach with GIP. Retatrutide is now investigating the potential of a third pathway, while cagrilintide research is examining what happens when amylin signaling is added to the picture.

The results are worth following, and future clinical trials will help determine how these approaches compare over time.

At Pep Compass, the goal is to make that research easier to understand without the exaggerated claims, confusing terminology, or promises that often surround the peptide market.

Explore more at Pep Compass

Visit our Peptide Research Resources page for additional educational information, published studies, and research terminology.

Disclaimer: This article is for educational and scientific research purposes only and does not constitute medical advice. Investigational compounds are not FDA-approved for human use. Research products are not substitutes for FDA-approved medications.